Inhaled Rentosertib (INS018_055) Phase 1 Design
ATS 2026
Study Design of a Phase 1, Randomized, Double blind, Placebo-controlled Study to Assess the Safety,
Tolerability, and Pharmacokinetics of Inhaled Rentosertib (INS018_055), A Novel AI-Generated TNIK Inhibitor